

CORRECTION

Open Access



Correction: Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma

Junfeng Liu^{1,2,3,4†}, Xi Li^{1,2,4*†}, Jiawen Chen^{1,2,3,4†}, Jingpei Guo^{1,2,3,4}, Hui Guo^{1,2,4}, Xiaoting Zhang^{1,2,3,4}, Jinming Fan^{1,2,3,4}, Ke Zhang^{1,2,3,4}, Junjie Mao^{1,2,4*} and Bin Zhou^{1,2,3,4*}

Correction: *Journal of Nanobiotechnology* (2024)

22:338

<https://doi.org/10.1186/s12951-024-02579-1>

In this article the wrong figure appeared as Fig. 6:
author corrections in the title of the graph in panel E and

[†]Junfeng Liu, Xi Li and Jiawen Chen have contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s12951-024-02579-1>.

*Correspondence:

Xi Li

lixi57@mail.sysu.edu.cn

Junjie Mao

maojunj@ mail.sysu.edu.cn

Bin Zhou

zhoub2@mail.sysu.edu.cn

¹ Center of Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China

² Institute of Interventional Radiology, Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China

³ Center of Cerebrovascular Disease, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China


⁴ Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

in the image in panel H were not implemented due to a typesetting mistake. Figure 6 should have appeared as shown below.

Uncorrected figure






Fig. 6 Combining BT-NPs@PLEL with anti-PD-L1 treatment for inhibition in residual tumors after iRFA. **A** Schematic representation of treatment of residual tumor after iRFA in C57/BL6 mice. **B** Bioluminescence images of mice with residual tumors after iRFA after different treatments on days 0, 10, and 20 ($n = 3$). **C** Bioluminescence signals of mice in each group on day 0, 10, and 20 ($n = 3$). **D** Tumor volume of residual tumors after iRFA in different groups ($n = 6$). **E** The weight of residual tumors on day 21 after different treatments ($n = 6$). **F** Survival analysis of experimental mice in different groups ($n = 6$). **G** Representative Flow cytometry plots and proportions of CD8+ T cells on day 7 ($n = 6$). **H** Representative flow cytometry plots and proportions of Granzyme B+ cells on day 7 ($n = 6$). ns, not significant * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Corrected figure

The original article has been corrected. The publisher apologises to the authors and readers for the inconvenience caused by this error.

Published: 2 August 2024

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.